http://orcid.org/0000-0002-1359-8828
References
- Anzenbacherova E, Anzenbacher P, Svoboda Z, et al. (2003). Minipig as a model for drug metabolism in man: comparison of in vitro and in vivo metabolism of propafenone. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 147:155–9.
- Botsch S, Gautier JC, Beaune P, et al. (1993). Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol 43:120–6.
- Capucci A, Boriani G. (1995). Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal. Drug Saf 12:55–72.
- Hege HG, Hollmann M, Kaumeier S, Lietz H. (1984). The metabolic fate of 2H-labelled propafenone in man. Eur J Drug Metab Pharmacokinet 9:41–55.
- Hiroi T, Chow T, Imaoka S, Funae Y. (2002). Catalytic specificity of CYP2D isoforms in rat and human. Drug Metab Dispos 30:970–6.
- Kobayashi K, Urashima K, Shimada N, Chiba K. (2003). Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: study with cDNA-expressed systems of the rat. Drug Metab Dispos 31:833–6.
- Kobayashi S, Murray S, Watson D, et al. (1989). The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochem Pharmacol 38:2795–9.
- Komura H, Iwaki M. (2005). Nonlinear pharmacokinetics of propafenone in rats and humans: application of a substrate depletion assay using hepatocytes for assessment of nonlinearity. Drug Metab Dispos 33:726–32.
- Martignoni M, Groothuis GM, de Kanter R. (2006). Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875–94.
- Muralidharan G, Hawes EM, McKay G, Midha KK. (1991). Quinine is a more potent inhibitor than quinidine in rat of the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase. Xenobiotica 21:1441–50.
- Nagayoshi H, Murayama N, Kakimoto K, et al. (2019). Site-specific oxidation of flavanone and flavone by cytochrome P450 2A6 in human liver microsomes. Xenobiotica 49:791–802.
- Narimatsu S, Arai T, Masubuchi Y, et al. (2001). Inactivation of rat cytochrome P450 2D enzyme by a further metabolite of 4-hydroxypropranolol, the major and active metabolite of propranolol. Biol Pharm Bull 24:988–94.
- Tan W, Li Q, McKay G, Semple HA. (1998). Identification and determination of phase I metabolites of propafenone in rat liver perfusate. J Pharm Biomed Anal 16:991–1003.
- Uehara S, Ishii S, Uno Y, et al. (2017). Regio- and stereo-selective oxidation of a cardiovascular drug, metoprolol, mediated by cytochrome P450 2D and 3A enzymes in marmoset livers. Drug Metab Dispos 45:896–9.
- Wang A, Stout CD, Zhang Q and Johnson EF (2015) Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding. J Biol Chem 290:5092–104.
- Wijnen PA, Op den Buijsch RA, Drent M, et al. (2007). Review article: the prevalence and clinical relevance of cytochrome P450 polymorphisms. Aliment Pharmacol Ther 26:211–9.
- Williams JA, Hyland R, Jones BC, et al. (2004). Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201–8.
- Zhou Q, Yao TW, Zeng S. (2001). Chiral metabolism of propafenone in rat hepatic microsomes treated with two inducers. World J. Gastroenterol 7:830–5.
- Zuber R, Anzenbacherova E, Anzenbacher P. (2002). Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 6:189–98.